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Abstract
Introduction: Due to their immunomodulatory properties, mesenchymal stromal cells (MSCs) have been used for
auto-immune disease treatment. Crohn disease (CD) and ulcerative colitis are two major inflammatory bowel diseases
(IBDs), resulting from pathological immune responses to environmental or microbial antigens. Preclinical and clinical
studies have suggested that MSC-based cellular therapy hold promising potential for IBD treatment. However, open
issues include the selection of the proper cell dose, the source and the optimal route of administration of MSCs for
more effective results. Platelet lysate has gained clinical interest due to its efficacy in accelerating wound healing. Thus,
we propose to combine the administration of MSCs with a human umbilical cord blood-derived platelet lysate (hCBPL)
as a novel strategy to improve MSC-based therapy for IBD resolution.
Methods: Colitis was induced in 8-week-old C57BL/6J mice by daily oral administration of dextran sulphate sodium (DSS)
(1.5 % w/v in tap water) for 9 days. MSCs were isolated from adipose tissue of CD patients (adCD-MSCs), expanded in
proliferation medium, resuspended in hCBPL or PBS and administrated via enema for three times (1 × 106 cells/mouse/time)
every other day starting on day +7 from DSS induction. The colitis evolution was evaluated by daily monitoring of body
weight, stool consistency and bleeding. Histopathological analysis was performed. Inflammatory cytokine plasma levels were
determined. adCD-MSCs stained with lipophilic membrane dye Nile Red, were injected in DSS mice as described above.
Colon section of mice sacrificed 24 hours after last cell administration, were analyzed by confocal microscopy.
Results:We found that adCD-MSCs could be easily isolated and expanded from CD patients. Upon injection, adCD-MSCs
exerted a therapeutic effect on DSS-induced colitis. Moreover, hCBPL increased adCD-MSCs efficacy by significantly
reducing colitis scores, extension of the colon inflamed area and plasma levels of inflammatory mediators. Finally, Nile
Red staining of MSCs is very efficient, stable and does not impair their vitality and function. Nile Red-labelling was clearly
detected in the colitic area of adCD-MSCs injected mice and it was significantly brighter in the colon sections of mice
that had received adCD-MSCs/hCBPL.
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Introduction
Mesenchymal stromal cells (MSCs) are multipotent adult
stem cells [1] which can differentiate in vitro and in vivo
into several tissue lineages originating from the three ger-
minal layers [2, 3]. MSCs are reported to be immunoprivi-
leged as well as immunosuppressive by inhibiting the
activation, proliferation, and function of immune cells by
different mechanisms of action [4–7]. These features
make MSCs an increasingly attractive model for cellular
therapy, bioengineering, and gene therapy [8]. Indeed, sev-
eral preclinical studies have shown that MSCs can be used
therapeutically to repair damaged tissues [9, 10]. Initially,
MSCs were thought to mediate tissue and organ repair by
virtue of their multilineage differentiation potential. How-
ever, it is now widely believed that in response to tissue in-
jury, MSCs home to the site of damage to support tissue
repair through the production of trophic factors, including
growth factors, cytokines, and antioxidants, which also
provide the basis for their capacity to modulate immune
response [11]. In recent years, owing to their immuno-
modulatory properties, MSC transplantation has been
used for the treatment of graft-versus-host disease
(GVHD) following allogeneic stem cell transplantation,
and several autoimmune diseases [12–16]. Inflammatory
bowel disease (IBD), including Crohn's disease (CD) and
ulcerative colitis (UC), is a chronic and relapsing auto-
immune disorder. Although the etiology of IBD is not yet
fully defined, it is generally agreed that a complex inter-
play between local immune reactions and environmental
factors contribute, in genetically susceptible individuals, to
disease initiation and progression [17]. Despite the
advancement in IBD treatment, the current situation is
still unsatisfactory. Indeed, poor results have been ob-
tained in IBD patients with the use of anti-inflammatory
drugs (e.g., tumor necrosis factor (TNF) inhibitors), which
have been associated with poor and transient response.
Furthermore, in 1/3 of patients, CD is complicated by
perianal fistulas which rarely heal spontaneously or after
medical treatment. Therefore, in most cases, surgical
colon resection is still the ultimate alternative [18, 19].
Preclinical studies, performed using human MSCs in
murine models [20–25], showed that MSCs are effective
in ameliorating colitis severity by exerting an anti-
inflammatory and/or immunosuppressive effect. Clinical
trials demonstrated that autologous [26–30] or allogeneic
[31] MSC transplantation is feasible and safe for the treat-
ment of fistulas [26–30] or luminal disease [31] in patients
with refractory CD. Although, the limited numbers of pa-
tients analyzed in each study do not allow conclusive
demonstration of the effectiveness of the treatment, ob-
tained results have suggested that MSC-based therapy
holds promising potential for tissue regeneration and local
anti-inflammatory effects in the treatment of IBD. Thus,
in the attempt to improve the efficacy of MSC treatment,
ongoing studies aim at evaluating the optimal source, the
proper dose, and the route of MSC administration. MSCs
can be isolated and expanded from several tissues includ-
ing bone marrow (BM), adipose tissue, and umbilical cord
blood (CB) [1]. Besides the BM, which is widely used in dif-
ferent experimental protocols and clinical trials and is con-
sidered a reference source, MSCs isolated from adipose
tissue (ad-MSCs) have emerged as an attractive alternative
for cell therapy, because of their prompt availability. ad-
MSCs show proliferative capacity and differentiation
potential similar to BM-derived MSCs [32]. Furthermore,
immunosuppressive properties of ad-MSCs were compar-
able with [33], if not higher than [34, 35], those of BM-
MSCs. ad-MSCs can efficiently control the GVHD in an in
vivo mouse model [36], opening new perspectives for the
clinical use of ad-MSCs in autoimmune diseases.
Platelet lysate has recently been proposed as substitute
for fetal bovine serum (FBS) in MSC expansion for thera-
peutic purpose [37, 38]. Furthermore, platelet-rich plasma
has gained clinical interest owing to its efficacy in accelerat-
ing wound healing and bone regeneration [39–42].
Here, we isolated MSCs from adipose tissue of CD pa-
tients (adCD-MSCs), and tested their efficacy in a
murine model of dextran sulfate sodium (DSS)-induced
experimental colitis (EC) [43]. We decided to combine
the administration of adCD-MSCs with a human umbil-
ical cord blood-derived platelet lysate (hCBPL). Indeed,
we aimed to verify whether adCD-MSCs are effective in
reducing the clinical signs of disease in a murine model
of EC, and to test the administration of adCD-MSCs in
combination with hCBPL as a novel strategy to improve
MSC-based therapy for IBD resolution.
We found that adCD-MSCs can be easily isolated and
expanded from CD patients and that hCBPL improved
the efficacy of adCD-MSC-based treatment in ameliorat-
ing DSS-induced colitis.
Materials and methods
Isolation and expansion of ad-MSCs
After Ethics Committee approval (Independent Ethic
Committee of the Azienda Ospedaliero-Universitaria
Policlinico Sant’Orsola Malpighi of Bologna, approval
number 1834/2013) and informed consent, ad-MSCs
were obtained from four patients with CD, by surgical
excision of healthy perifistula or subcutaneous area in
sterile conditions or from the lower abdomen of four
healthy female donors (as healthy donor controls), and
processed as described previously [44]. Additional file 1
summarizes demographic data for experimental samples.
Each patient gave written informed consent in accord-
ance with the Declaration of Helsinki. Briefly, the adi-
pose tissues were washed three times with phosphate
saline buffer (PBS) and incubated with 1 % collagenase
type 1 for 45 minutes at 37 °C. Mature adipocytes and
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undigested tissue fragments were separated from pellets
of stromal vascular fraction (SVF) by centrifugation at
500 × g for 15 minutes. SVF cells were resuspended in
culture medium (Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 1 % penicillin/streptomycin,
L-glutamine and 10 % FBS), plated and maintained in a
humidified incubator at 37 °C and 5 % CO2. All nonadher-
ent cells were removed after 24 hours. Medium was chan-
ged every 3–4 days until they reached 70–80 % confluence.
Cells were then trypsinized (Lonza, Verviers, Belgium),
replated at a density of 4000 cells/cm2, and used for experi-
ments within passages 3–4. At the end of each passage
(from passages 1 to 4) adCD-MSCs (n = 4) and MSCs from
adipose tissue of healthy donors (adHD-MSCs; n = 4) were
harvested and counted, and the population doubling (PD)
rate was determined using the following formula:
PD ¼ log10 Nð Þ= log10 2ð Þ
where N is the ratio between the harvested cells and the
seeded cells. The PD for each passage was calculated and
added to the PD of the previous passages to generate data
for cumulative PD.
Immunophenotypical characterization of MSCs
For immunophenotype studies, dual-color immunofluores-
cence was performed using the following panel of phyco-
erythrin (PE)-conjugated or fluorescein isothiocyanate
(FITC)-conjugated monoclonal antibodies: anti-human
CD14, anti-human CD13, anti-human HLA-DR, anti-
human CD34, and anti-human CD73 (BD Biosciences, Buc-
cinasco, Italy); and anti-human CD105, anti-human CD44,
anti-human CD45, anti-human CD90, and anti-human
CD29 (Chemicon, Temecula, CA, USA). Negative controls
were isotype-matched irrelevant monoclonal antibodies
(BD Biosciences). MSCs (5 × 105) were incubated in the
dark for 15 minutes at 4 °C in PBS–1 % bovine serum albu-
min (BSA). Cells were rinsed in PBS and analyzed using a
BD Accuri C6 flow cytometer (BD Biosciences). A mini-
mum of 10,000 events was collected in list mode on FCS
Express 4 Flow Research Edition Software (De Novo soft-
ware, Glendale, CA, USA).
Cell viability and proliferation assay
Trypan blue exclusion assay was used to determine the
number of viable cells in each culture. Cell viability was
determined by direct counting in a Burker chamber.
Cells excluding the dye were counted as viable.
Cell proliferation was determined by CellTiter 96
AQueous One Solution Cell Proliferation Assay (Promega
Italia, Milan, Italy). In brief, MSCs were seeded into a 96-
well microplate at a density of 10,000 cells/cm2 24 hours
before the addition of the MTS solution (tetrazolium
compound and phenazine methosulfate). Next, the cells
were incubated for 1 hour at 37 °C in 5 % humidified
CO2. Optical density value was measured using a mi-
croplate reader ELISA (Multiskan Ex; Thermo Electron
Corporation, San Josè, CA, USA) at a wavelength of
492 nm. Each sample was measured in triplicate wells.
MSC adipogenic and osteogenic differentiation
To induce adipogenic differentiation, adCD-MSCs were
seeded at 2.1 × 104 cells/cm2 in a Lab-Tek II coverglass
chamber (Nalge-Nunc, Roskilde, Denmark) and grown for
3 days in Adipogenic induction medium (Lonza) containing
additional human insulin, L-glutamine, (MCGS) Mesenchy-
mal Cell Growth Serum, dexamethasone, indomethacin, 3-
isobutyl-methyl-xanthine, penicillin/streptomycin followed
by 3 days in adipogenic maintenance medium containing
human insulin, L-glutamine, MCGS, penicillin/strepto-
mycin. Both steps were repeated up to day 18 when
cell cultures were stopped for histological staining. Fat
droplets within adipocytes were identified using the
Oil Red O staining method as described previously
[45]. Briefly, cells were fixed in 10 % paraformaldehyde
(PFA) in PBS for 1 hour at room temperature and
rinsed in 60 % isopropanol. The isopropanol was then
removed and the wells were completely dried and
stained with a 0.6 % (w/v) Oil Red O solution (Sigma
Aldrich, Saint Louis, MO, USA) for 15 minutes at
room temperature with gentle shaking.
To induce osteogenic differentiation, adCD-MSCs were
seeded at 3.1 × 103 cells/cm2 and grown in Osteogenic
Differentiation medium (Lonza) containing L-glutamine,
MCGS, dexamethasone, ascorbate, β-glycerophosphate,
penicillin/streptomycin. The media ware replaced every
3–4 days. Cell cultures were stopped at day 21 (3 weeks)
for histological staining. Calcium deposition was deter-
mined using Alizarin red staining as described previously
[45]. Briefly, cells were fixed in 10 % PFA in PBS for 15
minutes at room temperature, and then rinsed with PBS
and distilled water. Fixed cultures were stained with 40
mM Alizarin red solution (Sigma Aldrich), pH 4.2, for 75
minutes at room temperature with gentle shaking and
rinsed with distilled water.
Nile Red MSC labeling
adCD-MSCs were stained with Nile Red, a lipophilic
membrane dye (Sigma Aldrich), dissolved in dimethyl
sulfoxide (DMSO; 0.4 mg/ml), and added to the medium
at the final concentration of 0.5 % v/v. adCD-MSCs were
washed in PBS and incubated with Nile Red for 15 hours
at 37 °C in 5 % humidified CO2. After incubation, the
cells were harvested at different time points (15, 24, 48,
72, and 120 hours), washed in PBS by centrifuging at
700 × g for 5 minutes, and analyzed. Nile Red fluorescence
emission was measured by flow cytometry (FACSCanto™
II; BD Bioscences). The data analysis was carried out
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with the use of FACSDiva software (BD Biosciences, Buc-
cinasco, Italy). For confocal microscopy analysis, adCD-
MSCs (15,000/cm2) were incubated with Nile Red
added to the culture medium at the final concentration
of 0.5 % v/v, and grown on the coverslips for 15–72
hours. After incubation, MSCs were washed three times
with PBS and fixed with 4 % PFA. After washing, cells
slides were mounted in glycerol–PBS medium containing
50 mg/ml DABCO (1,4-diazabicyclo[2.2.2]octane). Con-
focal fluorescent images were obtained by a confocal
microscope (LEICA TCS SP5; Leica Microsystems GmbH,
Wetzlar, Germany) equipped with an argon/krypton ion
laser. Nile Red was excited at 543 nm and the emission
was collected in the spectral range from 650 to 700 nm.
Optical sections were obtained at increments of 0.45 μm
on the z axis and were digitized with a scanning mode for-
mat of 1024 × 1024 pixels. The image processing and
quantitative evaluation of Nile Red intensity were per-
formed using Leica TCS software (Leica Microsystems
GmbH, Wetzlar, Germany). Negative controls consisted of
samples not incubated with Nile Red. Fifteen images were
analyzed for each tested condition.
hCBPL preparation
CB units were collected from healthy newborns in plastic
bags containing 29 ml citrate-phosphate-dextrose anti-
coagulant (Macopharma, Mouvaux, France) by trained
midwives from vaginal deliveries and cesarean sections
after informed written consent was obtained from the par-
ents [46]. The Milano Cord Blood Bank is a public bank
approved by the Health Regional Authority and certified
for Cellular Therapy Product Collection, Processing,
and Administration (Foundation for the Accreditation
of Cellular Therapy- Joint Accreditation Committee-
International Society for Cellular Therapy & European
Group for Blood and Marrow Transplantation Inter-
national Standards).
All of the CB collections were performed only after suc-
cessful deliveries from healthy newborns with APGAR
(Appearance, Pulse, Grimace, Activity, Respiration) scores
between 9 and 10. CB units were processed within 24 ± 2
hours of collection to isolate platelets.
The CB units were centrifuged at 550 × g for 10
minutes to sediment red and white cells and to concen-
trate most of the platelets in the supernatant plasma.
The resulting platelet fraction was then centrifuged at
2000 × g for 10 minutes to obtain a platelet pellet. This
platelet fraction was diluted in an appropriate volume of
supernatant (platelet-poor plasma) to a final concentra-
tion of 2 × 106 platelets/μl. The platelets were then sub-
jected to three cycles of freezing at −80 °C and thawing
at 37 °C, and they were centrifuged at 2000 × g to
produce the platelet lysate (patent procedure US 2011/
0123503) [47].
Animal maintenance
Eight-week-old male C57BL/6 mice were purchased
from Charles River Laboratories (Lecco, Italy). Animals
were housed in a controlled environment in collective
cages, containing two mice each, at 22 ± 2 °C and 50 %
humidity under a 12-hour light/dark cycle. Mice were
allowed to acclimate to these conditions for at least 14
days before being randomized into experimental groups
and had free access to food and water throughout the
study. The experiments, approved by the institutional re-
view board of the University of Bologna (approval num-
ber 22-78-2013), were performed according to Italian
and European guidelines.
Induction of experimental colitis and study design
Colitis was induced in C57BL/6J mice by oral adminis-
tration of DSS (TdB Consultancy AB, Uppsala, Sweden)
as described previously [43]. Briefly, DSS-treated mice
received DSS in tap water (1.5 % DSS w/v). DSS–tap
water was freshly prepared every day and administered
to mice for 9 days and the average amount of DSS taken
was recorded daily. adCD-MSCs were expanded in prolif-
eration medium supplemented with 10 % FBS as described
before, resuspended in hCBPL or PBS, and then adminis-
trated via enema three times (1 × 106 cells/mouse/time)
every other day starting on day +7 from DSS induction.
This cell preparation protocol is compliant with the pro-
cedure we shall follow in the pending clinical trial. The
animals were randomly assigned into the following groups
of four mice each: CTR, mice received no treatment (con-
trol group); DSS+PBS, mice received DSS in tap water (1.5
%) for 9 days (on days 7, 9, and 11, mice received an
enema administration of 150 μl PBS alone); DSS+adCD-
MSCs, mice received DSS in tap water (1.5 %) for 9 days
(on days 7, 9, and 11, mice received an enema administra-
tion of human adCD-MSCs (1 × 106 cells/mouse/day)
resuspended in 150 μl PBS); DSS+adCD-MSCs/hCBPL,
mice received DSS in tap water (1.5 %) for 9 days (on
days 7, 9, and 11, mice received an enema administra-
tion of adCD-MSCs (1 × 106 cells/mouse/day) resus-
pended in 150 μl hCBPL); and DSS+hCBPL, mice
received DSS in tap water (1.5 %) for 9 days (on days 7,
9, and 11, mice received an enema administration of
150 μl hCBPL). Before MSC administration, mice
were mildly anesthetized using Zoletil-100 (10 mg/kg;
Virbac, Carros, France), and Xilor (2.5 mg/kg; Bio98,
Milan, Italy) by intramuscular injection. MSCs were ad-
ministered via a 16G venous catheter (diameter 2 mm,
length 48 mm; BD Bioscience, Buccinasco, Italy) that
was advanced through the rectum into the colon, until
the tip was 10 mm proximal to the anus. A venous
catheter was applied to a 1 ml syringe and the MSC
suspension was gently injected into the rectum. After
MSC administration, mice were held by the tail in a
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vertical position for 30 seconds and monitored for at
least 10 minutes, to ensure that the cell suspension was
not ejected. The first set of experiments was carried
out only with the first three experimental groups. The
colitis evolution was monitored by daily recording
of the body weight change of the animal study. In the
second set of experiments, clinical assessment of
inflammation was performed by daily monitoring of
the general health condition, body weight, stool
consistency, and bleeding. The Disease Activity Index
(DAI) was evaluated daily by adding scores of stool
consistency to scores of weight loss and occult blood
and by averaging the scores of all mice in each group.
Additional file 2 summarizes the criteria used to assign
the scores. All experiments were repeated two or three
times.
Histopathological analysis
All mice were anesthetized as described before and
sacrificed by cervical dislocation on day +18 or +22
(or day +12 in Nile Red-labeled cell experiments). The
colon was excised, rinsed with saline solution, fixed in 10
% formalin, and embedded in paraffin wax or Optimal
Cutting Temperature compound. Tissue sections (5 μm
thick) were collected on coated slides and stained with
hematoxylin and eosin (H&E). Histopathological scores
were blindly determined as reported in Obermeier et al.
[48]. Mice were scored individually. Ten sections for
each animal were evaluated. Each group score repre-
sented the mean of at least four mice in each group.
Additional file 3 summarizes the criteria used to as-
sign histopathological damage scores. The histological
damage score represents the sum of the epithelial
damage and infiltration score, ranging from 0 (un-
affected) to 8 (severe colitis).
Cytokine measurements
Blood was collected from the caudal vein in sodium
citrate-containing Eppendorf tubes. Plasma was ob-
tained by centrifugation at 1000 × g for 15 minutes.
Cytokine levels were determined using Luminex tech-
nology (BioPlex; Biorad, Segrate, Italy). The six-plexed
pro mouse kit (interleukin (IL)-6, TNFα, IL-17, IL-1β,
interferon gamma (IFNγ), IL-10;) was performed in
96-well filter plates following the manufacturer’s in-
structions as described previously [43]. The samples
were analyzed in the Bioplex 200 instrument (Biorad,
Segrate, Italy) and the concentration were estimated
from a standard curve and expressed as pg/ml.
Data analysis
Data are presented as mean ± SEM of at least three
independent determinations. Statistical differences between
groups were determined by one-way analysis of variance
followed by Bonferroni’s post-hoc test for multiple com-
parison. All analyses were performed using GraphPad
Prism software (version 6.0; La Jolla, CA, USA). p <0.05
was considered to indicate statistical significance.
Results
adCD-MSCs show typical MSC biological properties
We first isolated and expanded adCD-MSCs and charac-
terized their biological properties. adCD-MSCs showed a
typical spindle-shape morphology (Fig. 1a) and differen-
tiation potential (Fig. 1b, c). We then measured the
adCD-MSC proliferative capacity from isolation (pas-
sage 0) to passage 4 by calculating the PD rate. In the
analyzed samples (n = 4), we found no significant dif-
ferences as compared with MSCs derived from adipose
tissue of healthy donors (adHD-MSCs, n = 4) (p value
not significant) (Fig. 1d). Sample demographics are
shown in Additional file 1. Regarding the immunophe-
notype, the majority of adCD-MSCs were, as expected,
positive for CD73, CD13 (>98 %), CD105, CD90, CD44,
and CD29 (>93 %), while they presented a low expres-
sion of HLA-DR (<2 %) and of hematopoietic markers
such as CD34 (<2 %), CD45 (<1 %), and CD14 (<2 %)
(Fig. 1e–i). A similar immunophenotype was observed
in adHD-MSCs (data not shown). adCD-MSCs can thus
be easily isolated and expanded from adipose tissue of
CD patients and they show typical MSC biological
properties according to the minimal criteria to define
MSCs derived from adipose tissue [49].
adCD-MSC therapy ameliorates colitis in a DSS mouse
model of EC
To test their potential therapeutic activity, adCD-MSCs
were administrated by enema in a mouse model of DSS-
induced EC, which we described recently [43]. In this
model, mice presented initial and mild clinical signs of
disease after the end of DSS treatment (day +9). The
most evident clinical signs were recorded between
days +9 and +15 [43], with a significant weight loss
that peaked between days +11 and +14 [43] (see also
Figs. 2 and 3). Thus, we decided to inject adCD-MSCs
three times, every other day, starting from day +7 from
DSS induction (Fig. 2). DSS+adCD-MSC-treated mice
showed significantly reduced weight loss and faster body
weight recovery compared with DSS+PBS-treated mice
from day +11 (time of the last adCD-MSC administration)
to the end of the observation, at each time point (Fig. 2)
(p <0.01). adCD-MSCs are therefore effective in ameliorat-
ing DSS-induced colitis in our model of EC. Furthermore,
we do not detect any side effect referring to the MSC ad-
ministration by enema.
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hCBPL potentiates the effect of adCD-MSCs in an EC
mouse model
Next, we investigated the activity of hCBPL to improve
the efficacy of adCD-MSC treatment according to the
same experimental design shown in Fig. 2. As reported
in Fig. 3, the weight loss detected daily in the group of
mice treated with DSS+adCD-MSCs/hCBPL was signifi-
cantly lower than the weight loss of mice treated with
DSS+PBS (p <0.01) or DSS+adCD-MSCs. Conversely,
hCBPL alone in the absence of MSCs did not show any
therapeutic effect (Fig. 3a).
Moreover, the DAI including clinical parameters of
inflammation (weight loss, diarrhea, and rectal bleeding)
[43] (see also Additional file 2) was daily recorded. DAI
results (Fig. 3b, representative time points) confirmed the
data obtained from the analysis of body weight change. In
particular, in DSS+adCD-MSC/hCBPL-treated mice the
DAI had already been significantly reduced at the end of
MSC treatment (day +11) (p <0.05) and was further sig-
nificantly reduced during the recovery phase (day +18), as
compared with DSS+PBS-treated mice (p <0.05) (Fig. 3b).
In DSS+hCBPL-treated mice, at each time point the DAI
Fig. 1 adCD-MSCs show typical MSC biological properties. a Representative field of exponential growing culture of adCD-MSCs. b Alizarin red
staining of adCD-MSCs cultured for 3 weeks in osteogenic conditions and c Oil red O staining of adCD-MSCs cultured for 3 weeks in adipogenic
conditions. Magnification 10×; scale bar, 100 μm. d Comparison of cumulative population doublings (CPD) calculated in adipose tissue-derived
MSC cultures obtained from healthy donors (adHD-MSC) or adipose tissue-derived MSC cultures obtained from CD patients (adCD-MSC) at each
passage. Results expressed as the mean ± SEM calculated from data obtained from four independent samples. Differences are not significant
(p value not significant). e–i Flow cytometric immunophenotype of adCD-MSCs at passage 3. Representative dot plots. The analysis shows
a predominant population of cells positive for CD90, CD29, CD73, CD105, CD13, and CD44, and negative for CD34, CD45, CD14, and HLA-DR. FITC,
fluorescein isothiocyanate, PE phycoerythrin
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was not significantly different as compared with DSS+PBS-
treated mice (p value not significant).
Histopathological examination of the colon sections in
the distal and proximal tracts showed that adCD-MSC
treatment significantly reduced the extension and the se-
verity of the inflamed area and the infiltration of inflam-
matory cells (Fig. 4e, f ), as compared with DSS-treated
mice that received PBS only (Fig. 4a, b). Furthermore,
DSS-treated mice that received adCD-MSCs/hCBPL
showed only slight signs of colon inflammation and
restored a normal appearance at day +22 (Fig. 4g, h). In
contrast, as expected, DSS-treated mice that received
hCBPL only showed a histopathological pattern similar
to DSS+PBS-treated mice. A quantitative evaluation of
histological damage was performed as described in
Materials and methods and in Additional file 3. Histo-
logical score data (Table 1) confirmed that adCD-MSC
treatment significantly reduced the epithelial damage
and the infiltration of inflammatory cells as compared
with DSS-treated mice that received PBS only. Further-
more, as expected from qualitative analysis, adCD-MSC/
hCBPL-treated mice showed the lower histological score
(p <0.05, compared with the DSS+PBS group) (Table 1).
DSS-treated mice that received hCBPL only or PBS only
showed a very similar histological score (p value not
significant) (Table 1).
A putative mechanism of action for MSC therapy in
autoimmune diseases is the downregulation of proin-
flammatory cytokines. Thus, we determined the
plasma levels of IL-1β, IL-6, IL-17, IL-10, IFNγ, and
TNFα in study mice. Notably, we found that adCD-
MSCs reduced the systemic inflammatory responses
in EC mice from day +11 to day +22 after DSS adminis-
tration and their activity was significantly enhanced by
hCBPL (Fig. 5). In particular, adCD-MSC/hCBPL adminis-
tration significantly reduced the levels of all tested
inflammatory cytokines, at days +18 and +22, if compared
with cytokine levels in DSS-treated mice that received
PBS only (p <0.05). Furthermore, the TNFα and IL-6
levels at days +18 and +22 (Fig. 5b, c) and the IL-17 level
at day +22 (Fig. 5d) were decreased significantly in adCD-
MSC/hCBPL-treated mice even with respect to adCD-
MSC-treated mice (p <0.05) (Fig. 5). At each time point,
the administration of hCBPL only did not cause significant
changes in any cytokine levels compared with the admin-
istration of PBS only (p value not significant) (Fig. 5).
Labeled adCD-MSCs/hCBPL localize in the injured tissue
To better understand adCD-MSC trafficking, we set up
a novel method for efficient cell labeling. We marked
adCD-MSCs with Nile Red, a lipophilic membrane dye,
commonly used for staining cellular lipid structures [50],
Fig. 2 Treatment with adCD-MSCs protects against DSS-induced colitis. Mice received 1.5 % of DSS with their drinking water for 9 days.
At days +7, +9, and +11 from DSS induction, mice are treated by enema with adCD-MSCs (1 × 106 cells/mice/time) or phosphate saline
buffer (PBS) alone. (Top) Schematic of the experiment. The evolution of colitis is monitored by body weight change expressed as a percentage of the
initial body weight at day 0 (100 %). CTR, healthy control mice (dotted black line); DSS+adCD-MSCs, DSS-treated mice which received
adCD-MSCs (blue line); DSS+PBS, DSS-treated mice which received PBS alone (red line). Data expressed as mean ± standard error of the
mean (SEM). n = 4 mice per group. CTR vs. DSS+PBS, ****p <0.0001; DSS+adCD-MSCs vs. DSS+PBS, **p <0.01. adCD-MSC mesenchymal
stromal cell isolated from adipose tissue of Crohn’s disease patients, DSS dextran sulfate sodium
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and we analyzed labeled cells by confocal microscopy
and flow cytometry. Nile Red-labeled cells are viable and
maintained similar phenotypic, proliferative, and differ-
entiative properties as compared with unlabeled cells
(see Additional file 4). Furthermore, confocal images
showed that adCD-MSCs were evenly stained by Nile
Red. Flow cytometry analysis confirmed that Nile Red
staining of adCD-MSCs was very efficient (99.9 % of
positive cells 15 hours after the staining) and stable up
to 72 hours. Fluorescence intensity of Nile Red-labeled
adCD-MSCs, as indicated by both confocal microscopy
and flow cytometry, significantly decreased at 120 hours
post labeling (Fig. 6).
Nile Red-labeled adCD-MSCs were injected by enema
in DSS mice with the same schedule as the previous
experiments. Injected mice were sacrificed 24 hours after
last cell administration. Colon was then collected and
tissue sections were analyzed by confocal microscopy.
Fig. 3 hCBPL improves the therapeutic efficacy of adCD-MSCs. Mice received 1.5 % of DSS with their drinking water for 9 days. At days +7, +9,
and +11 from DSS induction, mice were treated by enema with adCD-MSCs (1 × 106 cells/mice/time) with or without human umbilical cord
blood-derived platelet lysate (hCBPL) or phosphate saline buffer (PBS) alone. Clinical evolution of colitis is monitored by body weight change and
DAI evaluation. a Body weight changes during the course of the experiment are expressed as the percentage of the initial body weight
at day +0. (Top) Schematic of the experiment. CTR, healthy control mice (dotted black line); DSS+adCD-MSCs, DSS-treated mice which
received adCD-MSCs (blue line); DSS+adCD-MSCs/hCBPL, DSS-treated mice which received adCD-MSCs resuspended in hCBPL (green line);
DSS+hCBPL, DSS-treated mice which received hCBPL alone (pink line); DSS+PBS, DSS-treated mice which received PBS (red line). Data
expressed as mean ± SEM. n = 4–12 mice per group. CTR vs. DSS+PBS, ****p <0.0001; DSS+adCD-MSCs/hCBPL vs. DSS+PBS, **p <0.01;
hCBPL vs. DSS+PBS, p value not significant. b DAI calculated by the combined score of weight loss, stool consistency, and bleeding, as
detailed in Additional file 1. DAI is evaluated daily from day +7 (first administration of adCD-MSCs or adCD-MSCs/hCBPL or PBS or hCBPL)
to day +18. Representative time points are shown. Data expressed as mean ± SEM. n = 4–12 mice per group. DSS+adCD-MSCs and DSS+adCD-MSCs/
hCBPL vs. DSS+PBS, *p <0.05. adCD-MSC mesenchymal stromal cell isolated from adipose tissue of Crohn’s disease patients, DSS dextran
sulfate sodium
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We found that a strong fluorescence was clearly vis-
ible in the tissue sections of adCD-MSC-injected
mice (Fig. 7b), while a low fluorescence background
was shown in DSS+PBS-treated mice (Fig. 7a). More
importantly, the fluorescence signal in the colon sec-
tions of mice that received adCD-MSCs/hCBPL
(Fig. 7c) was significantly brighter than in colon sec-
tions of mice administered adCD-MSCs alone, as
confirmed by quantitative analysis of fluorescence in-
tensity (p <0.05) (Fig. 7f ). Merged images of sections
from consecutive segment stained with H&E (Fig. 7d)
showed that the fluorescence of Nile Red labeling
was present mainly in the muscular ayers surrounding
the colon injury (Fig. 7e). Overall, these data suggested
that hCBPL stimulated the localization and/or transit of
adCD-MSCs in the target tissue.
Fig. 4 adCD-MSCs/hCBPL prevent DSS-induced pathology. Photomicrographs of H&E-stained paraffin sections of mouse colons treated as
described before and harvested at day +22. Two representative examples are shown for each condition. Sections from a, b mice that received
DSS, c, d mice that received DSS+hCBPL, e, f mice that received DSS+adCD-MSCs, and g, h mice that received adCD-MSCs/hCBPL. Magnification
50×; scale bar, 200 μm. adCD-MSC mesenchymal stromal cell isolated from adipose tissue of Crohn’s disease patients, DSS dextran sulfate sodium,
hCBPL human umbilical cord blood-derived platelet lysate, PBS phosphate saline buffer
Table 1 Histological damage score: quantitative evaluation of
histological damage in study mice
Mouse group Mean ± SEM
DSS+PBS 7.10 ± 0.23
DSS+hCBPL 6.90 ± 0.28
DSS+adCD-MSCs 5.20 ± 0.29*
DSS+adCD-MSCs/hCBPL 4.70 ± 0.21*
Histological damage score was blindly determined from hematoxylin and
eosin-stained paraffin sections of mouse colons harvested at day +22. Ten sections
from each mouse and at least four mice for each group were evaluated. Data were
presented as mean ± standard error of the mean (SEM). Histology was
scored as indicated in Material and methods and in Additional file 3.
Histological score represents the sum of the epithelial damage and infiltration
score, ranging from 0 (unaffected) to 8 (severe colitis)
*Significant differences vs. DSS+PBS group, p <0.05
adCD-MSC mesenchymal stromal cell isolated from adipose tissue of Crohn’s
disease patients, DSS dextran sulfate sodium, hCBPL human umbilical cord
blood-derived platelet lysate, PBS phosphate saline buffer
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Fig. 5 adCD-MSCs/hCBPL decrease systemic inflammatory response in DSS-induced colitis mouse model. Plasma was obtained from mice blood,
collected from the caudal vein. a–f Cytokine levels (IL-1β, IL-17, TNFα, IL-6, IL-10, IFNγ) were measured using Bioplex assay at the start of
the experiment (day +0), at the end of DSS treatment (day+9), after the administration of PBS (black column), hCBPL alone (white column),
adCD-MSCs (light gray column), or adCD-MSCs/hCBPL (dark gray column) (day +11), at day +18, and at the end of the experiment (day +22). Data
expressed as mean ± SEM. n = 4–8 mice per group. *p <0.05 with respect to DSS+PBS group; #p <0.05 in the comparison between the MSC groups.
adCD-MSC mesenchymal stromal cell isolated from adipose tissue of Crohn’s disease patients, DSS dextran sulfate sodium, hCBPL human umbilical cord
blood-derived platelet lysate, IFN-γ interferon gamma, IL interleukin, PBS phosphate saline buffer, TNFα tumor necrosis factor alpha
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Discussion
In spite of many recent improvements, current therapy
for IBD is far from satisfactory [18, 19]. Thus, new and
more effective therapeutic approaches are needed. In the
present study, we proposed a novel strategy to improve
the efficacy of MSC-based cellular therapy for IBD treat-
ment. While previous reports demonstrated that human
MSCs ameliorate both clinical and histopathological se-
verity of EC [20–24], our study introduces innovative as-
pects aimed to increase MSC effectiveness. Indeed, we
Fig. 6 adCD-MSCs can be efficiently labeled by Nile Red staining. Fluorescence intensity and distribution of Nile Red staining. a–d Representative
micrograph of stained cell cultures and e–h three-dimensional histograms of confocal analysis of fluorescence intensity (expressed as fluorescence
intensity/pixel) for each time point. Fluorescence intensity of Nile Red-labeled adCD-MSCs analyzed by flow cytometry is high at i 15 hours, l 24
hours, and m 72 hours and n decreased significantly at 120 hours post labeling. Magnification 40×; scale bar, 20 μm
Forte et al. Stem Cell Research & Therapy  (2015) 6:170 Page 11 of 16
directly tested the efficacy of MSCs expanded from adipose
tissue of CD patients in a murine model of EC. We found
that adCD-MSCs can be easily isolated and expanded,
maintaining their biological features. Our results demon-
strated that adCD-MSCs are effective in reducing clinical
and pathological signs of colitis. These findings are relevant
in view of the use of autologous cells for the treatment of
IBD patients.
Regarding in vivo study, there is no ideal animal model
resembling human IBD, but certainly DSS-induced
colitis is the most commonly used and has been vali-
dated as a proper model for the translation of mice data
to human IBD. In our study we induced colitis using a
reduced percentage of DSS (i.e., 1.5 %), converse to the
murine model so far widely adopted (i.e., 3–5 % DSS).
Thus, our model does not lead animals to death while
presenting the peculiar changes in the colon structure,
ulceration, dilatation, damage of the crypts, and inflam-
matory infiltrate (see Fig. 4a, b), but it is characterized
by mild intestinal damage. This feature makes it very
Fig. 7 In vivo administration of Nile Red-labeled adCD-MSCs in DSS-treated colitic mice. DSS-treated mice were subjected to enema administration of
Nile Red-stained adCD-MSCs. Colon tissue sections were collected 24 hours after the last MSC administration and were analyzed by confocal or optical
microscopy. a DSS-treated mice colon sections show a low fluorescence background, in the absence of adCD-MSCs. Fluorescence signals
in the presence of b Nile Red-stained adCD-MSCs or c adCD-MSCs/hCBPL. d Sections from consecutive segment were fixed and stained
with H&E. e Merged images show that Nile Red fluorescence is present mainly in the muscular layers surrounding the colon injury. f Fluorescence
quantification is presented as mean fluorescence intensity (± SEM). Data are representative of three mice for each experimental group and 15 acquired
sections for each experimental condition. *p <0.05. Magnification 20×; scale bar, 150 μm. adCD-MSC mesenchymal stromal cell isolated from adipose
tissue of Crohn’s disease patients, DSS dextran sulfate sodium, hCBPL human umbilical cord blood-derived platelet lysate, PBS phosphate saline buffer
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suitable and accurate for studying the dynamics of colitis
during clinical remission and hence for evaluating thera-
peutic agent effects.
Here, we combined the administration of ad-MSCs
with hCBPL. Usually these hemocomponents are ob-
tained from platelets derived from peripheral blood.
Recently, we developed a procedure to obtain a plate-
let product from umbilical CB [51]. CB platelets are
able to release several growth factors contained in
their granules such as platelet-derived growth factor
PDGF-AB and PDGF-BB, vascular endothelial growth
factor, hepatocyte growth factor, basic fibroblast
growth factor, and transforming growth factor beta1
[47]. In addition, their trophic and immunomodula-
tory activities in animal models have already been
tested by showing that CB platelets contain factors
more likely to support soft tissue repair if compared
with the peripheral blood counterpart [51]. Platelet
lysate may also replace animal serum for the prepar-
ation of MSCs intended for clinical trials. However,
previous studies demonstrated the proinflammatory
activity of peripheral blood-derived platelet lysate
(PBPL) [52]. Therefore, PBPL would not be an ideal
addition for MSC preparation for cell therapy strat-
egies in autoimmune disease. In our study, we used
selected batches of FBS for MSC expansion to adhere as
much as possible to the manufacturing protocol which
will be used for the upcoming phase I trial. Indeed, the
use of hCBPL is not feasible for large-scale MSC produc-
tion for clinical trials. In the present paper, we showed
that, also in an animal model of EC, hCBPL enhanced the
regenerative effect of MSC-based treatment. adCD-MSCs
clearly contribute to tissue repair as indicated by histo-
pathological analysis (Fig. 4 and Table 1). We could
speculate that, when coadministered with MSCs,
hCBPL synergistically stimulates MSC effects. Further-
more, the activity of hCBPL in combination with ad-
MSCs could explain the significant downregulation of
T-helper type 1 cytokines such as IFNγ and TNFα, indi-
cating that their beneficial effects rely, at least in part,
on the anti-inflammatory mechanism. We also found
that the circulating level of IL-10 followed the same
trend of the other cytokines after MSC administration.
Contrasting results regarding this issue have been
reported recently. Specifically, some reports showed
that local colonic anti-inflammatory cytokine IL-10
increased after MSC transplantation [20–22, 53]. Con-
versely, other studies showed that the IL-10 level
remained unchanged after MSC administration in a
DSS model but increased in a 2,4,6-trinitrobenzene sul-
fonic acid model [25]. Circulating IL-10 levels are not
affected during the acute phase of DSS-induced colitis,
but strongly increase during the chronic phase [54].
Since our DSS model induces mild colitis with a very
short acute phase and a long chronic-like recovery
phase, it is not surprising that MSC treatment—capable
of ameliorating colitis, shortening the chronic phase,
and accelerating the recovery—also reduces circulating
IL-10 levels and/or probably impairs IL-10 accumulation.
This suggests that, in our model, the MSC anti-
inflammatory mechanism is probably IL-10 independent.
We then proposed a novel method for MSC label-
ing. For the first time, we employed Nile Red, a lipo-
philic membrane dye, commonly used for staining
cellular lipid structures [50], to label viable MSCs and
to track their presence/passage in the target tissue.
Nile Red staining of MSCs is very efficient, is stable,
and does not impair their vitality and function. Nile
Red labeling was clearly detected in vivo after 24
hours from MSC transplantation in study mice. More-
over, the addition of hCBPL resulted in a significant
increase in the amount of fluorescence signal detected
in the colitic area. Notably, hCBPL showed greater
potency than adult platelet-rich plasma preparations
in stimulating MSC migration in a chemotaxis assay
[55]. However, other mechanisms (i.e., stimulation of
proliferation and/or increased survival of labeled cells
in the injured area) may be involved. Furthermore, in
vitro experiments showed that Nile Red-labeled
adCD-MSCs were able to transfer lipophilic dye to
unlabeled human colon mucosal epithelial cells but not
vice versa (data not shown). The fluorescence we observed
in the colon section of study mice thus relies on the pres-
ence and/or the transit of Nile Red-labeled adCD-MSCs
in the site of injury, although we cannot rule out the
hypothesis that the pattern is due to resident murine cells
which received fluorescence by Nile Red-labeled adCD-
MSCs.
Our results also demonstrated that MSCs can be ad-
ministered safely and successfully by topical injection by
enema. So far, murine [56–60] and human [20–25]
MSCs have been injected in IBD murine models, intra-
venously or intraperitoneally. The topical injection al-
lows the direct delivery of MSCs to the injured area
where their beneficial effects are required. These find-
ings are clinically relevant, especially in the perspective
of using MSCs in those patients in whom CD is compli-
cated by the development of fistulas, and are refractory
to the current treatments.Recent phase I–II clinical stud-
ies suggested that local injection of MSCs in the sub-
mucosa in fistulizing lesions produces a considerable
therapeutic benefit [27, 28, 30]. The small colon size in
mice prevents the use of needles of a diameter sufficient
to maintain the viability of the cells, and therefore sub-
mucosal injection of MSCs is not feasible in this model.
However, the presence of Nile Red labeling in the muscu-
lar layers surrounding the colon injury after 24 hours from
injection suggests the predictivity of our murine model.
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Conclusions
We isolated and expanded, ex vivo, and successfully
injected by enema adCD-MSCs into DSS-treated mice.
adCD-MSCs are effective in ameliorating the patho-
logical and clinical features of DSS-induced colitis.
hCBPL significantly improved adCD-MSC therapeutic
effects. Local delivery of adCD-MSCs with hCBPL sup-
port may thus be considered a potentially safe and useful
strategy for the treatment of IBD refractory to the
current treatments.
Additional files
Additional file 1: Table S1. Presenting sample demographics.
Summary of the main features of CD patients from which adCD-MSCs
were isolated. Data for healthy donors from which adHD-MSCs were
isolated for the comparison of biological properties are also shown.
(DOC 34 kb)
Additional file 2: Table S2. Presenting DAI score criteria. Summary of
the criteria used to assign the scores added to determine the DAI in
mice daily. (DOCX 13 kb)
Additional file 3: Table S3. Presenting histological damage score
criteria. Summary of the criteria used to assign the scores added to
determine the histological damage score. (DOC 31 kb)
Additional file 4: Figure S1. Showing that Nile Red-labeled adCD-MSCs
are viable and maintain phenotypic and differentiative properties as
compared with unlabelled cells. Proliferation rate (cell titer assay),
immunophenotype (flow cytometry), and differentiation potential (Alizarin
red and Oil red O staining) of Nile Red-labeled adCD-MSCs (adCD-MSCs+NR)
compared with unlabeled adCD-MSCs. Nile Red-labeled adCD-MSCs are
viable and maintain phenotypic and differentiative properties compared with
unlabeled cells. a Proliferation rate is evaluated by cell titer assay and
expressed as fold-change taking the value of unlabeled cells at each time
point as 1. Data expressed as mean ± SEM of at least three experiments. All
differences are not significant (p value not significant). NR Nile Red.
b Flow cytometric immunophenotype of Nile Red-labeled adCD-MSCs
(adCD-MSCs+NR) is similar to that of unlabeled adCD-MSCs. Data
expressed as mean ± SEM of at least two experiments. All differences
are not significant (p value not significant). As a proof of differentiation
potential, osteogenic and adipogenic process are shown. Alizarin red and
Oil red O staining of unlabeled c, d and Nile Red-labeled e, f adCD-MSCs
cultured for 3 weeks in osteogenic c, e and adipogenic conditions d, f.
Magnification 20×; scale bar, 100 μm. (PDF 1843 kb)
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